Neurogene reaffirms Embolden data for 2H 2027, cash runway into Q1 2029
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
1 story
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)